Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15

Development of point-of-care testing devices to improve clozapine prescribing habits and patient outcomes

Authors Kalaria SN, Kelly DL

Received 23 May 2019

Accepted for publication 30 July 2019

Published 20 August 2019 Volume 2019:15 Pages 2365—2370

DOI https://doi.org/10.2147/NDT.S216803

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Roger Pinder


Shamir N Kalaria,1 Deanna L Kelly2

1Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA; 2Department of Psychiatry, School of Medicine, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA

Correspondence: Deanna L Kelly
Maryland Psychiatric Research Center (MPRC), 55 Wade Avenue, Catonsville 21228, MD, USA
Tel +1 410 402 6861
Email dlkelly@som.umaryland.edu

Abstract: Although clozapine has demonstrated superior efficacy in patients with schizophrenia and other serious mental health illness, drug utilization rates are significantly low due to safety concerns and administration challenges. Previous research indicates that current barriers to clozapine use include lack of confidence and knowledge by prescriber, therapeutic monitoring requirements, lack of support and infrastructure to for adequate monitoring and patient adherence, and inadequate understanding of clozapine’s benefit-risk profile by policy makers and payers. One potential solution to optimizing clozapine therapy and improving clinical outcomes is the use of point-of-care testing (POCT) devices. Although the drug development process for currently used therapeutics is widely acknowledged, little is known regarding the development of POCT devices by the clinical community. The aim of this review is to provide a summary of the regulatory approval process and current availability of POCT devices for monitoring clozapine therapeutics. The potential role of POCT devices in clinical trials to inform personalized dosing strategies and improve patient outcomes will also be discussed.

Keywords: clozapine, schizophrenia, patient outcomes, point-of-care testing devices, regulatory, therapeutic drug monitoring

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]